{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:02:59Z","timestamp":1793037779408,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Guidelines recommend combining macrolides with \u03b2-lactam antibiotics for moderate-to-high severity community-acquired pneumonia (CAP); however, macrolides pose risks of adverse events and anti-microbial resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed electronic health data from 8872 adults hospitalized with CAP in Oxfordshire, UK (2016-2024), initially treated with amoxicillin or co-amoxiclav. Using inverse probability treatment weighting, we examined the effects of adjunctive macrolides on 30-day all-cause mortality, time to hospital discharge, and changes in Sequential Organ Failure Assessment (SOFA) score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was no evidence of an association between adjunctive macrolides and 30-day mortality (marginal odds ratio 1.05 [95% CI 0.75-1.47] for amoxicillin with vs. without macrolide; 1.12 [0.93-1.34] for co-amoxiclav with vs. without macrolide); and no evidence of a difference in time to discharge (restricted mean days lost +1.76 days [\u22121.66, +5.19] for amoxicillin, +0.44 days [\u22121.63, +2.51] for co-amoxiclav). Macrolide use was not associated with SOFA score decreases. Results were consistent across severity sub-groups and sensitivity analyses with missing covariates imputed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>At a population level, the addition of macrolides was not associated with improved clinical outcomes for patients with CAP. The potential benefits of additional macrolides should be weighed against the risks of adverse effects and anti-microbial resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae639","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T18:14:09Z","timestamp":1735064049000},"page":"e713-e722","source":"Crossref","is-referenced-by-count":13,"title":["Addition of Macrolide Antibiotics for Hospital Treatment of Community-Acquired Pneumonia"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-529X","authenticated-orcid":false,"given":"Jia","family":"Wei","sequence":"first","affiliation":[{"name":"Nuffield Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-8509","authenticated-orcid":false,"given":"A Sarah","family":"Walker","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine"},{"name":"National Institute for Health and Care Research Oxford Biomedical Research Centre"},{"name":"National Institute for Health and Care Research Health Protection Research Unit in Healthcare-Associated Infections and Antimicrobial Resistance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5095-6367","authenticated-orcid":false,"given":"David W","family":"Eyre","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research Oxford Biomedical Research Centre"},{"name":"National Institute for Health and Care Research Health Protection Research Unit in Healthcare-Associated Infections and Antimicrobial Resistance"},{"name":"Big Data Institute, Nuffield Department of Population Health, University of Oxford"},{"name":"Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2025041514222624300_jiae639-B1","author":"National Institute for Health and Care Excellence"},{"key":"2025041514222624300_jiae639-B2","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"2025041514222624300_jiae639-B3","doi-asserted-by":"crossref","first-page":"2200735","DOI":"10.1183\/13993003.00735-2022","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"61","author":"Martin-Loeches","year":"2023","journal-title":"Eur Respir J"},{"key":"2025041514222624300_jiae639-B4","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041514222624300_jiae639-B5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","article-title":"Immunomodulation by macrolides: therapeutic potential for critical care","volume":"8","author":"Reijnders","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025041514222624300_jiae639-B6","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2014.4304","article-title":"Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia","volume":"311","author":"Mortensen","year":"2014","journal-title":"JAMA"},{"key":"2025041514222624300_jiae639-B7","doi-asserted-by":"crossref","first-page":"f1235","DOI":"10.1136\/bmj.f1235","article-title":"Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies","volume":"346","author":"Schembri","year":"2013","journal-title":"BMJ"},{"key":"2025041514222624300_jiae639-B8","first-page":"CD011825","article-title":"Adverse events in people taking macrolide antibiotics versus placebo for any indication","volume":"1","author":"Hansen","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041514222624300_jiae639-B9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/429242","article-title":"Predicting antimicrobial resistance in invasive pneumococcal infections","volume":"40","author":"Vanderkooi","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025041514222624300_jiae639-B10","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S1473-3099(18)30444-4","article-title":"Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review","volume":"19","author":"O\u2019Brien","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025041514222624300_jiae639-B11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkp088","article-title":"Impact of intravenous {beta}-lactam\/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia","volume":"63","author":"Tessmer","year":"2009","journal-title":"J. Antimicrob Chemother"},{"key":"2025041514222624300_jiae639-B12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"key":"2025041514222624300_jiae639-B13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","article-title":"Effect of combined \u03b2-lactam\/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia","volume":"155","author":"Ceccato","year":"2019","journal-title":"Chest"},{"key":"2025041514222624300_jiae639-B14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Mart\u00ednez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2025041514222624300_jiae639-B15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jamapediatrics.2017.3225","article-title":"Effectiveness of \u03b2-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia","volume":"171","author":"Williams","year":"2017","journal-title":"JAMA Pediatr"},{"key":"2025041514222624300_jiae639-B16","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1186\/cc13095","article-title":"Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance","volume":"17","author":"Adrie","year":"2013","journal-title":"Crit Care"},{"key":"2025041514222624300_jiae639-B17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1183\/09031936.00031007","article-title":"The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis","volume":"30","author":"Paul","year":"2007","journal-title":"Eur Respir J"},{"key":"2025041514222624300_jiae639-B18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"2025041514222624300_jiae639-B19","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","article-title":"\u03b2-lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis","volume":"69","author":"Nie","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025041514222624300_jiae639-B20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"key":"2025041514222624300_jiae639-B21","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2025041514222624300_jiae639-B22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-2600(23)00412-5","article-title":"Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial","volume":"12","author":"Giamarellos-Bourboulis","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025041514222624300_jiae639-B23","doi-asserted-by":"crossref","first-page":"106161","DOI":"10.1016\/j.jinf.2024.106161","article-title":"No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia","volume":"88","author":"Wei","year":"2024","journal-title":"J Infect"},{"key":"2025041514222624300_jiae639-B24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"2025041514222624300_jiae639-B25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(17)30782-1","article-title":"Mortality risks associated with emergency admissions during weekends and public holidays: an analysis of electronic health records","volume":"390","author":"Walker","year":"2017","journal-title":"Lancet"},{"key":"2025041514222624300_jiae639-B26","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"key":"2025041514222624300_jiae639-B27","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1214\/19-AOAS1282","article-title":"Propensity score weighting for causal inference with multiple treatments","volume":"13","author":"Li","year":"2019","journal-title":"Ann Appl Stat"},{"key":"2025041514222624300_jiae639-B28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2025041514222624300_jiae639-B29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2307\/271063","article-title":"Bayesian model selection in social research","volume":"25","author":"Raftery","year":"1995","journal-title":"Sociol Methodol"},{"key":"2025041514222624300_jiae639-B30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/aje\/kwq472","article-title":"Implementation of G-computation on a simulated data set: demonstration of a causal inference technique","volume":"173","author":"Snowden","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2025041514222624300_jiae639-B31","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/sim.8896","article-title":"Estimation and modeling of the restricted mean time lost in the presence of competing risks","volume":"40","author":"Conner","year":"2021","journal-title":"Stat Med"},{"key":"2025041514222624300_jiae639-B32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2025041514222624300_jiae639-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2025041514222624300_jiae639-B34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.32614\/RJ-2021-073","article-title":"MatchThem: matching and weighting after multiple imputation","volume":"13","author":"Pishgar","year":"2021","journal-title":"R J"},{"key":"2025041514222624300_jiae639-B35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","article-title":"Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"2025041514222624300_jiae639-B36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025041514222624300_jiae639-B37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1378\/chest.13-1607","article-title":"Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia","volume":"145","author":"Laserna","year":"2014","journal-title":"Chest"},{"key":"2025041514222624300_jiae639-B38","doi-asserted-by":"crossref","first-page":"e39435","DOI":"10.7554\/eLife.39435","article-title":"The distribution of antibiotic use and its association with antibiotic resistance","volume":"7","author":"Olesen","year":"2018","journal-title":"eLife"},{"key":"2025041514222624300_jiae639-B39","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"2025041514222624300_jiae639-B40","doi-asserted-by":"crossref","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ"},{"key":"2025041514222624300_jiae639-B41","volume-title":"FDA drug safety communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms","author":"US Food and Drug Administration","year":"2019"},{"key":"2025041514222624300_jiae639-B42","doi-asserted-by":"crossref","first-page":"110649","DOI":"10.1016\/j.celrep.2022.110649","article-title":"Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults","volume":"39","author":"Anthony","year":"2022","journal-title":"Cell Rep"},{"key":"2025041514222624300_jiae639-B43","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2006.10.018","article-title":"International classification of diseases codes showed modest sensitivity for detecting community-acquired pneumonia","volume":"60","author":"van de Garde","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"2025041514222624300_jiae639-B44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annepidem.2013.02.005","article-title":"Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data","volume":"23","author":"Drahos","year":"2013","journal-title":"Ann Epidemiol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae639\/61272317\/jiae639.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/4\/e713\/61272317\/jiae639.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/4\/e713\/61272317\/jiae639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:51:35Z","timestamp":1744728695000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/4\/e713\/7932176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,24]]},"published-print":{"date-parts":[[2025,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae639","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,15]]},"published":{"date-parts":[[2024,12,24]]}}}